Bouf, Three years after the entry of the first generic and we still hold the majority of the market. Why is that? This is not a drug that can be produced In mass cheaply. The standard generic playbook doesn't work on this. Amarin has been able to compete. The market will grow over time. Generic companies will most likely have their piece and we ours. What the potential size of that market will be is key for determining the success of our investment. Sleven,
Bouf; hope you don’t mind but are you retired or still working? If you’re retired you should shop around for an insurer that covers Vascepa brand. If you’re still working then perhaps you could get a supplemental plan?
News 
Market Data 
Discover 
